10-K: Prothena 2025 Annual Report: Pipeline Progress Amid Restructuring

Prothena's 2025 annual report highlights advancements in its partnered neurodegenerative and amyloidosis programs, alongside a significant workforce reduction and a net loss of $244.1 million.

Summary

• Reported a net loss of $244.1 million for the year ended December 31, 2025, compared to $122.3 million in 2024.
• Total revenue decreased significantly to $9.7 million in 2025 from $135.2 million in 2024, primarily due to lower collaboration revenue from BMS.
• Research and development (R&D) expenses decreased by $87.7 million to $134.9 million in 2025, mainly due to the wind-down of the PRX012 program and birtamimab.
• Incurred $30.1 million in restructuring costs in 2025, following the discontinuation of birtamimab development and a 63% workforce reduction in June 2025.
• Cash and cash equivalents stood at $307.5 million as of December 31, 2025, deemed sufficient for at least the next twelve months.
• Prasinezumab (partnered with Roche) advanced to Phase 3 (PARAISO trial initiated Q4 2025) for early Parkinson's disease, building on positive trends from Phase 2b PADOVA and PASADENA trials.
• Coramitug (acquired by Novo Nordisk) initiated Phase 3 (CLEOPATTRA trial initiated Q4 2025) for ATTR-CM, following positive Phase 2 results showing a 48% reduction in NT-proBNP levels.
• BMS-986446 (partnered with BMS) received FDA Fast Track designation in October 2025 and is in Phase 2 (TargetTau-1 trial initiated Q1 2024) for early Alzheimer's disease.
• PRX019 (partnered with BMS) initiated a Phase 1 clinical trial in November 2024 after IND clearance in December 2023.
• Wholly-owned programs include preclinical TDP-43 CYTOPE for ALS and PRX123, a dual A-Tau vaccine, which received IND clearance and Fast Track designation in January 2024.
• PRX012, a wholly-owned anti-A antibody for Alzheimer's, showed doseand time-dependent reductions in amyloid plaque in Phase 1, but was associated with higher ARIA-E rates.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period for Prothena, marked by significant financial losses and a major program discontinuation, despite some positive advancements in partnered clinical trials. The substantial workforce reduction reflects a necessary but difficult strategic pivot, and future capital needs remain a concern.

Positives

• Prasinezumab advanced to Phase 3 for early Parkinson's disease, indicating continued confidence from partner Roche.
• Coramitug initiated Phase 3 for ATTR-CM, supported by positive Phase 2 data showing a statistically significant 48% reduction in NT-proBNP levels.
• BMS-986446 received FDA Fast Track designation and is progressing in Phase 2 for early Alzheimer's disease.
• PRX019 initiated Phase 1 clinical trials, expanding the partnered pipeline with BMS.
• Wholly-owned dual A-Tau vaccine PRX123 received IND clearance and Fast Track designation, highlighting potential for future development.
• Development of CYTOPE technology shows promise for targeting previously undruggable intracellular disease targets.
• Cash and cash equivalents of $307.5 million are projected to be sufficient for at least the next twelve months.

Negatives

• Reported a significant net loss of $244.1 million in 2025, a substantial increase from $122.3 million in 2024.
• Total revenue decreased by 93% from $135.2 million in 2024 to $9.7 million in 2025.
• Discontinuation of birtamimab development in May 2025 due to failure to meet primary or secondary endpoints in the Phase 3 AFFIRM-AL clinical trial.
• Implemented a 63% workforce reduction in June 2025, incurring $30.1 million in restructuring costs.
• PRX012, despite showing amyloid plaque reduction, was associated with higher overall ARIA-E rates, making it less appropriate for the studied patient population.
• Anticipates incurring losses for the foreseeable future and will require additional capital to fund operations beyond the next twelve months.
• Interest income decreased by $11.7 million in 2025 due to lower interest rates and cash balances.

Risks

• Anticipates incurring losses for the foreseeable future and may never sustain profitability.
• Will require additional capital to fund operations, and inability to obtain such capital would prevent successful development and commercialization of drug candidates.
• Success is largely dependent on the success of research and development programs, which are prone to significant risks of failure.
• Collaborations (Roche, BMS, Novo Nordisk) might not realize anticipated benefits, including milestone payments, due to collaborators' discretion, strategic changes, or insufficient resources.
• Clinical trials may be prolonged, delayed, suspended, or terminated, increasing costs and delaying revenue.
• Even if approved, drug candidates may not achieve broad market acceptance.
• Inability to adequately protect or enforce intellectual property relating to drug candidates could harm commercialization efforts.
• Future success depends on the ability to retain key personnel and attract, retain, and motivate qualified personnel.
• Business operations may be adversely affected by disruptions beyond control, such as public health crises, geopolitical turmoil, or natural disasters.
• May experience breaches or disruptions of information technology systems or data, leading to loss of intellectual property or personal data.
• Changes in and failures to comply with U.S. and foreign privacy and data protection laws may adversely affect business.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable, potentially leading to denial of approval.
• FDA or other regulatory authorities may not accept data from trials conducted outside their jurisdiction.
• Even if approved in one country, may not receive approval or commercialize products in other countries.
• Ongoing regulatory requirements and review post-approval, with potential sanctions for non-compliance.
• Identification of side effects during development or post-market could lead to additional trials, labeling changes, or market withdrawal.
• Dealing with hazardous materials requires compliance with environmental laws, which can be expensive and restrict business.
• Intense competition in the pharmaceutical industry could render drug candidates noncompetitive or obsolete.
• Drug candidates approved as biologics may face biosimilar competition sooner than anticipated.
• May be unable to maintain benefits associated with Orphan Drug Designation, including market exclusivity.
• Fast Track designation does not guarantee faster development or approval.
• Subject to healthcare and other laws (anti-bribery, anti-kickback, fraud and abuse, false claims, physician payment transparency), non-compliance could lead to sanctions.
• Product liability or clinical trial claims could result in substantial uninsured or excess liabilities.
• Dependence on third parties to conduct clinical trials, who may not perform satisfactorily.
• Inability to establish additional strategic collaborations may alter research, development, and/or commercialization plans.
• No manufacturing capacity; dependence on third-party manufacturers for all drug supplies.
• Dependence on third-party suppliers for key raw materials.
• Subject to claims challenging inventorship or ownership of patents and other intellectual property.
• Inability to protect intellectual property rights throughout the world.
• Licenses from third parties may be terminated if obligations are not met.
• Litigation regarding patents and proprietary rights may be expensive and time-consuming.
• Inability to adequately prevent disclosure or misappropriation of trade secrets.
• Claims that employees, collaborators, or advisors have wrongfully used or disclosed third-party trade secrets.
• Intellectual property rights may not address all threats to competitive advantage.
• Market price of ordinary shares may fluctuate widely.
• Percentage ownership may be diluted in the future due to equity issuances.
• Inability to maintain effective internal controls could adversely affect business.
• Potential treatment as a passive foreign investment company (PFIC) for U.S. federal income tax purposes could result in adverse consequences to United States holders.
• Inability to successfully maintain tax rates due to changes in tax laws or audits.
• Irish law differs from U.S. laws, potentially affording less protection to shareholders and less ability for the board to control takeover proposals.
• Operation of the Irish Takeover Rules may affect the ability of certain parties to acquire ordinary shares.
• Irish law requires that shareholders renew every five years the authority of the Board of Directors to issue shares and to do so for cash without applying the statutory pre-emption right, with the next renewal deadline of May 17, 2027.
• Do not anticipate paying cash dividends, and accordingly, shareholders must rely on ordinary share appreciation for any return on investment.
• Dividends paid may be subject to Irish dividend withholding tax.
• Ordinary shares received by means of a gift or inheritance could be subject to Irish capital acquisitions tax.

Future Outlook

Prothena aims to continue building its biology-directed discovery engine targeting protein dysregulation, advance its pipeline of therapeutic candidates, and explore new partnership opportunities, particularly for its CYTOPE technology. The company expects to incur losses for the foreseeable future and will require additional capital beyond the next twelve months to fund operations and advance its drug candidates. Full year 2026 net cash used in operating and investing activities is projected to be approximately $50 million to $55 million.

Management Comments

• Our goal is to be a leading biotechnology company focused on the discovery and development of novel therapies to treat diseases caused by protein dysregulation.
• Our near-term plan is to continue to support our active clinical programs which are all partnered with large pharmaceutical companies, while investing in early-stage research programs and technology to create future partnership opportunities and collaborations.
• We intend to advance new discovery-stage therapeutics for other diseases of protein dysregulation with unmet medical needs.
• We are exploring potential partnership interest to advance PRX012 and our preclinical PRX012-TfR (transferrin receptor) antibody programs.
• We are exploring potential partnership interest to advance PRX123.
• Management believes that cash and cash equivalents at December 31, 2025, are sufficient to meet obligations for at least the next twelve months.

Industry Context

StockSavvy.ai notes that Prothena operates in the highly competitive neurodegenerative and rare peripheral amyloid diseases space, characterized by significant R&D investment and reliance on strategic partnerships with large pharmaceutical companies like Roche, BMS, and Novo Nordisk. The industry faces challenges in developing disease-modifying therapies for complex conditions like Parkinson's and Alzheimer's, where current treatments are often symptomatic. Prothena's focus on protein dysregulation and novel technologies like CYTOPE positions it within a key area of innovation, but also exposes it to high clinical trial risks and the need for substantial capital.

Comparison to Industry Standards

• Prasinezumab's Phase 2b PADOVA results (HR=0.84, p=0.0657 for primary endpoint; HR=0.79, p=0.0431 in levodopa subgroup) show potential clinical effect, positioning it as the first anti-alpha synuclein antibody to advance into late-stage development, which is a significant milestone compared to many failed attempts in this challenging area.
• Coramitug's Phase 2 data demonstrated a statistically significant 48% reduction in NT-proBNP levels, a key biomarker for cardiac function, which is a strong signal in ATTR-CM, a disease with high unmet need, and potentially complements existing TTR stabilizers.
• PRX012's Phase 1 data showed amyloid plaque reduction (mean to 27.47 centiloids at month 12, 9 of 12 participants reaching amyloid negativity below 24.1 CL at 18 months with 400mg dose), comparable to or exceeding amyloid negativity thresholds for FDA-approved anti-A antibodies (e.g., <30 CL or <24.1 CL). However, its higher ARIA-E rates present a safety challenge compared to existing therapies.
• The company's significant net losses and reliance on milestone payments and future capital raises are common for clinical-stage biotechnology companies, but the 63% workforce reduction and discontinuation of birtamimab highlight the high-risk nature of drug development.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.

Stakeholder Impact

• Shareholders: Significant net loss and workforce reduction could negatively impact share price. Dilution risk from future capital raises. Reliance on share appreciation for return as no dividends are anticipated. Irish law differences and takeover rules may affect shareholder rights and acquisition potential.
• Employees: 63% workforce reduction in June 2025 and anticipated further reductions in 2026. This impacts job security and morale.
• Customers/Patients: Discontinuation of birtamimab means no new treatment for AL amyloidosis from Prothena. Progress in partnered programs (Parkinson's, ATTR-CM, Alzheimer's) offers future treatment potential.
• Partners (Roche, BMS, Novo Nordisk): Continued collaboration and advancement of pipeline programs. Roche and Novo Nordisk initiated Phase 3 trials, indicating ongoing commitment. BMS also advancing programs.
• Creditors: Cash position deemed sufficient for next 12 months, but future capital needs imply potential for new debt or equity, which could affect credit profile.

Next Steps

• Continue supporting active clinical programs partnered with Roche, Novo Nordisk, and BMS.
• Invest in early-stage research programs and technology, including CYTOPE, to create future partnership opportunities.
• Advance new discovery-stage therapeutics for other diseases of protein dysregulation.
• Explore potential partnership interest for wholly-owned programs like PRX012 and PRX123.
• Renew Board's authority to issue shares and opt out of preemption rights by May 17, 2027.
• Reduce headcount by an additional 17 employees in 2026.
• Hold Annual General Meeting of Shareholders on May 14, 2026.

Key Dates

Recommendation

Prothena faces significant headwinds, including a substantial net loss, a major program discontinuation (birtamimab), and a large workforce reduction, which are clear negatives. However, the company has successfully advanced multiple key partnered programs (prasinezumab, coramitug, BMS-986446) into late-stage clinical trials, demonstrating continued external validation and potential for future milestone payments. The wholly-owned pipeline also shows promise with Fast Track designations for PRX123. Given the mixed bag of significant setbacks and promising pipeline progress, a 'hold' recommendation is appropriate. Investors should monitor the progress of the Phase 3 trials and the company's ability to secure additional capital and partnerships for its early-stage assets, especially given the higher ARIA-E rates observed with PRX012.

Keywords

biotechnology, neurodegenerative diseases, protein dysregulation, Parkinson's disease, Alzheimer's disease, ATTR amyloidosis, ALS, clinical trials, drug development, monoclonal antibody, CYTOPE technology, prasinezumab, coramitug, BMS-986446, PRX019, PRX012, PRX123, SEC filing, financial reporting, biopharmaceutical, Nasdaq, PRTA